Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $140.1152W HIGH $213.08
Volume
1.52 M
Value Traded
315.92 M
Short % Float
4.16%
+3.37%Week
+1.64%1 Month
+20.28%3 Month
+18.5%6 Month
-21.62%5 Year
+4,913.02%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
50.36 B
EPS (TTM)
3.45
P/E Ratio
52.90
Ent. Value
63.16 B
Total Shares
275.46 M
Float Shares
271.83 M
Insiders
0.20%
Institutions
99.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BDX Catalyst Timeline
Dated clinical, regulatory and corporate events for Becton, Dickinson and Company
Catalyst Timeline
Dated clinical, regulatory & corporate events for Becton, Dickinson and Company
1114Total events
12Upcoming
255Tier-1 (high impact)
2011 to 2031Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Ferass Abuzaina named worldwide president of BD Surgery business unit
▲Grant / FundingCorporate
BD to announce $10,000 grant to Maliheh Free Clinic as part of Sandy 70-year celebration
▲Enrollment CompleteTrial
Enrollment completed in PREVENT trial
prevention of incisional herniasource ↗
▲Product LaunchsemaglutidePost-Market
EMS and BD launch semaglutide therapy in Brazil
obesity and type 2 diabetessource ↗
▲Partnership / LicensesemaglutideCorporate
BD and EMS collaborate on semaglutide launch in Brazil
obesity and type 2 diabetessource ↗
▲Other Regulator MilestoneEx-US Regulatory
BD awarded Vizient Innovative Technology contract for CentroVena One™ Insertion System
▲Product LaunchPost-Market
Pyxis Pro Dispensing Solution to be rolled out across Europe in coming months
▲Manufacturing MilestoneCMC / Inspection
BD Neopak™ Glass Prefillable Syringe production to begin in Columbus, Nebraska
●Manufacturing MilestoneCMC / Inspection
Syringe samples for feasibility studies expected to be available
●Manufacturing MilestoneCMC / Inspection
Ypsomed to expand YpsoMate 5.5 platform and integrate BD Neopak XtraFlow 5.5mL syringe
▲First Patient DosedElyra™Trial
First clinical cases completed with Elyra™ Plus TFL System
kidney stone caresource ↗
◆Oral PresentationPresentation
BD to present at Bank of America Securities Health Care Conference
▲Other Regulator MilestoneEx-US Regulatory
Received CE Marking for Revello Vascular Covered Stent
iliac artery treatmentsource ↗
▲Other Regulator MilestoneEx-US Regulatory
Received CE Marking for Liverty TIPS Stent Graft
portal hypertensionsource ↗
◆Oral PresentationPresentation
First presentation of ARCH study data at SIR annual meeting
portal hypertensionsource ↗
◆Oral PresentationPresentation
Présentation des données de l'essai ARCH à la réunion SIR
hypertension portalesource ↗
▲Other Regulator MilestoneEx-US Regulatory
CE marking requested for Liverty TIPS Stent Graft
portal hypertensionsource ↗
▲PublicationPresentation
Study published in Journal of Clinical Medicine
nighttime urinary incontinencesource ↗
▲Full ResultsClinical Data
Four-week randomized trial results announced
nighttime urinary incontinencesource ↗
▲Other Regulator MilestoneEx-US Regulatory
CE marking application for Liverty™ TIPS Stent Graft
portal hypertensionsource ↗
●Other Regulator MilestoneEx-US Regulatory
Demande de marquage CE pour l'endoprothèse Liverty™ TIPS
hypertension portalesource ↗
▲Product LaunchPost-Market
BD launches HemoSphere Stream module for continuous non-invasive blood pressure monitoring
◆Trial InitiationTrial
Planned 1,000-patient immune profiling study expected to start this summer
Past FDA Catalysts and PDUFA Decisions
How BDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2002-10-07 | Chloraprep Triple Swabstick (chlorhexidine gluconate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D34 / 100
Pipeline Score
$369M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 56%
Mid Cap(rank 369 of 658)
Percentile Rank
Becton, Dickinson and Company faces pipeline headwinds (34/100), with $434M risk-adjusted pipeline value, led by CHG 2% w/v & IPA 70% v/v, swabstick in Topical Antisepsis (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CHG 2% w/v & IPA 70% v/v, swabstick Small moleculeCompletedNCT00799812 | Topical Antisepsis | Phase 3 | COMPLETED | 335 | Jun 19, 2008 |
Clinical Trial Results
Readouts, endpoints and source filings for every BDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| peripheral intravenous catheters (PIVCs) | 2021-02-02 | PIVC failure rate standard: 47.5%; PIVC failure rate BD solution: 34.8%; median time to failure standard: 30.0 hours; median time to failure BD solution: 50.4 hours; catheter colonization standard: 16.9%; catheter colonization BD solution: 0.9%; local infection standard: 1.2%; local infection BD solution: 0%Read More | First-of-its-Kind Randomized Clinical Trial Published in The Lancet Infectious Diseases Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust ...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Feld MichaelOfficer (EVP, Chief Revenue Officer) | Sell | -76 19,644 held | $183.70 | 09/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 3.3 % (57.1 %) | 27.55 M | 120.28 K | 70.85% ( 49.88 K) |
BDX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BDX ranks across every disease it competes in
Competitive Position is a premium feature
See how BDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBDX News
BDX▲ +1.4%today
BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
BD (Becton, Dickinson and Company) will host an audio webcast on November 5, 2026, to discuss its financial results for Q4 and the full year of fiscal 2026. The results will cover the period ending September 30, 2026, and will include updates on the company's operations and strategy. A news release and presentation materials will be available prior to the call.
Read more →BDX▲ +1.4%today
BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
BD (Becton, Dickinson and Company) celebrated 65 years of manufacturing in Canaan, Connecticut, where the first fully sterile, single-use disposable plastic syringe was produced. The facility has grown significantly, now employing over 500 people and producing more than 2 billion syringes annually. BD's commitment to innovation and community support was highlighted during the celebration, including a $10,000 grant to a local health center.
Read more →BDX▲ +1.4%today
BD Appoints Ferass Abuzaina as Worldwide President of Surgery
BD has appointed Ferass Abuzaina as the worldwide president of its Surgery business unit, effective immediately. Abuzaina, who has been with BD since 2013, will oversee global strategy and operations. His leadership is anticipated to enhance the company's growth and innovation in surgical solutions. He holds advanced degrees in Chemical Engineering and an MBA.
Read more →BDXBD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
BD (Becton, Dickinson and Company) celebrated 70 years of manufacturing in Sandy, Utah, highlighting its role in producing essential medical devices. The facility employs over 1,000 people and has significantly contributed to vascular access technology. BD has invested over $100 million in recent years to enhance operations and support community initiatives, including a $10,000 grant to the Maliheh Free Clinic.
Read more →BDXArthur Hu to Join BD as Chief Information and Digital Officer
BD has appointed Arthur Hu as its new Chief Information and Digital Officer, effective September 30. Hu, who has over 25 years of experience in technology and digital transformation, previously worked at Lenovo and McKinsey & Company. His role will focus on modernizing BD's operations and embedding AI into their processes. He succeeds Denise Russell Fleming, who will retire at the end of 2026.
Read more →BDXBD to Present at Wells Fargo 21st Annual Healthcare Conference
BD (Becton, Dickinson and Company) will present at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The presentation will be accessible via a live webcast on BD's investor relations website, with a replay available afterward. This event underscores BD's role in advancing healthcare through innovation.
Read more →BDXBD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
BD has appointed Gary Sorsher as the new Chief Quality Officer, effective September 8. Sorsher, with over 30 years of experience in quality leadership, previously served at Edwards Lifesciences. The announcement also includes the retirement of Jeff Silvestri, who has contributed significantly to BD's quality initiatives over his 25-year tenure.
Read more →BDXBD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
BD has completed enrollment in the PREVENT trial, a large-scale study assessing Phasix™ Mesh for preventing incisional hernias. The trial involved 477 patients across 32 sites in the U.S. and Europe, marking a significant step in addressing a common post-surgical complication. The study aims to generate evidence for regulatory submission to the FDA, with follow-ups planned for up to five years.
Read more →BDXEMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
BD and EMS have partnered to launch a semaglutide therapy in Brazil, enhancing access to GLP-1 treatments for obesity and type 2 diabetes. This collaboration leverages BD's advanced injection pen technology to ensure a reliable and user-friendly experience for patients. The initiative aims to address significant healthcare challenges in managing chronic diseases.
Read more →BDXBD Board Declares Dividend
BD (Becton, Dickinson and Company) has declared a quarterly dividend of $1.05 per share, payable on September 30, 2026. This dividend reflects an annual rate of $4.20 per share. BD continues to position itself as a leader in medical technology, emphasizing its role in enhancing healthcare outcomes globally.
Read more →BDXMike Garrison to Retire from BD
Dr. Michael Garrison will retire from BD after over 20 years of service, effective October 2. He has held various leadership roles, significantly impacting the company. A search for his successor is underway, and BioPharma Systems will report directly to the CEO, reflecting its strategic importance. Garrison expresses gratitude for his time at BD.
Read more →BDXBD to Announce Financial Results for its Third Quarter of Fiscal 2026
BD (Becton, Dickinson and Company) will announce its financial results for Q3 of fiscal 2026 on August 6, 2026. The announcement will be accompanied by an audio webcast at 8 a.m. ET, where management will discuss the results and provide updates on operations and strategy. A news release and presentation materials will be available prior to the call.
Read more →BDXBD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
BD's CentroVena One™ Insertion System has been awarded an Innovative Technology contract by Vizient, acknowledging its potential to improve central line insertion. The system's all-in-one design simplifies the procedure, enhancing safety and efficiency. This recognition reflects the growing demand for innovative solutions in healthcare delivery.
Read more →BDXBD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
BD has launched the Elyra™ Thulium Fiber Laser System, designed to improve efficiency and workflow in urology for kidney stone management. The system features advanced Thulium Fiber Laser technology, offering quieter operation and a smaller footprint. Positive initial feedback from clinical cases highlights its user-friendly design and safety features.
Read more →BDXPeter Menziuso Named EVP and President, BD Interventional
BD (Becton, Dickinson and Company) has appointed Peter Menziuso as executive vice president and president of BD Interventional, effective June 1. Menziuso, who has over 30 years of experience in global healthcare, previously led a $5 billion business at Johnson & Johnson Vision. His leadership is expected to enhance BD Interventional's growth and performance.
Read more →BDX▲ +5.9%on this news
BD Reports Second Quarter Fiscal 2026 Financial Results
BD (Becton, Dickinson and Company) reported strong financial results for the second quarter of fiscal 2026, with revenue, margins, and earnings per share surpassing expectations. The company has raised its full-year adjusted EPS guidance and reaffirmed revenue growth expectations, attributing this success to broad-based execution and strong performance from growth platforms. The results reflect the company's ongoing commitment to its New BD strategy post-spin-off of its Biosciences and Diagnostic Solutions business.
Read more →BDX▲ +5.9%on this newsshared move
BD Appoints Vitor Roque Chief Financial Officer
BD has appointed Vitor Roque as Chief Financial Officer, effective May 7, 2026. Roque, who has been serving as interim CFO since December 2025, has over 25 years of experience at BD. His leadership is expected to enhance financial performance and support the company's growth strategy. Roque emphasizes the importance of disciplined financial management in driving BD's future success.
Read more →BDXBD and Wellstar Advance Patient Care and Safety with Medication Management Powered by AI
BD has partnered with Wellstar Health System to enhance medication management through the integration of BD Pyxis™ Pro and BD Alaris™ platforms. This collaboration aims to improve safety and quality in medication delivery by providing clinicians with better accuracy and real-time insights. The use of AI technology will streamline workflows and empower healthcare professionals to focus on patient care.
Read more →About Becton, Dickinson and Company
HeadquartersONE BECTON DR, FRANKLIN LAKES, NJ, 07417-1880
Founded1897
BIOPHARMAWATCH ELITE PLUS
Trade the next BDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime